GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma AS (NAS:ASND) » Definitions » Short Interest

ASND (Ascendis Pharma AS) Short Interest


View and export this data going back to 2015. Start your Free Trial

What is Ascendis Pharma AS Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Ascendis Pharma AS's Short Interest

For the Biotechnology subindustry, Ascendis Pharma AS's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascendis Pharma AS's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Short Interest distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Short Interest falls into.


;
;

Ascendis Pharma AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma AS (NAS:ASND) » Definitions » Short Interest
Comparable Companies
TECH PCVX EXEL HALO JAZZ ROIV MDGL RVMD INCY SRPT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
ASND:Mexico A71:Germany A1SN34:Brazil
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Website
https://www.ascendispharma.com
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.